Eli Lilly obesity pill disappoints in trial, sending shares down 14%
Weight loss comes in at lower end of expectations and triggers stock boost for rival Novo Nordisk
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
